Use of cannabinoids in the treatment of epilepsy

Patent metadata

Field	Value
Publication number	US-11311498-B2
Application number	US-201514741829-A
Country	US
Kind code	B2
Filing date	Jun 17, 2015
Priority date	Jun 17, 2014
Publication date	Apr 26, 2022
Grant date	Apr 26, 2022

Abstract

The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

First claim

The invention claimed is:

1. A method of treating absence seizures in a subject diagnosed with an epilepsy selected from Lennox-Gastaut Syndrome, Myoclonic Absence Epilepsy, and Dravet Syndrome, comprising administering cannabidiol (CBD) to a subject, wherein the CBD is administered at a dose of from about 10 mg/kg/day to about 20 mg/kg/day, wherein the CBD has a purity of at least 98% (w/w) CBD and comprises no more than 0.15% (w/w) Δ9-tetrahydrocannabidiol.

2. The method according to claim 1 , wherein the absence seizures are myoclonic absence seizures.

3. The method according to claim 1 , wherein the epilepsy is treatment-resistant epilepsy (TRE).

4. The method according to claim 1 , wherein the CBD is administered in combination with one or more concomitant anti-epileptic drugs (AED).

5. The method according to claim 1 , wherein the subject is diagnosed with Lennox-Gastaut Syndrome.

6. The method according to claim 1 , wherein the subject is diagnosed with Dravet Syndrome.

7. The method according to claim 1 , wherein the subject is diagnosed with Myoclonic Absence Epilepsy.

8. The method according to claim 1 , wherein the CBD is a highly purified extract of cannabis.

9. The method according to claim 8 , wherein the extract further comprises up to 1% CBDV.

10. The method according to claim 1 , wherein the CBD is present as a synthetic compound.

11. The method according to claim 4 , wherein the one or more concomitant AED is selected from the group consisting of: sodium valproate; lamotrigine; clobazam; and clonazepam.

12. The method according to claim 4 , wherein the number of different concomitant anti-epileptic drugs that are used in combination with the CBD is reduced.

13. The method according to claim 4 , wherein the dose of the concomitant AED that is used in combination with the CBD is reduced.

14. A method of treating absence seizures in a subject diagnosed with Lennox-Gastaut Syndrome, comprising administering cannabidiol (CBD) to a subject, wherein the CBD is administered at a dose of from about 5 mg/kg/day to about 25 mg/kg/day, wherein the CBD has a purity of at least 98% (w/w) CBD and comprises no more than 0.15% (w/w) Δ9-tetrahydrocannabidiol.

15. A method of treating absence seizures in a subject diagnosed with Dravet Syndrome, comprising administering cannabidiol (CBD) to a subject, wherein the CBD is administered at a dose of from about 5 mg/kg/day to about 25 mg/kg/day, and wherein the CBD has a purity of at least 98% (w/w) CBD and comprises no more than 0.15% (w/w) Δ9-tetrahydrocannabidiol.

16. The method of claim 14 , wherein the dose of CBD is 10 mg/kg/day.

17. The method of claim 14 , wherein the dose of CBD is 20 mg/kg/day.

18. The method of claim 15 , wherein the dose of CBD is 10 mg/kg/day.

19. The method of claim 15 , wherein the dose of CBD is 20 mg/kg/day.

20. The method of claim 1 , wherein the dose of CBD is 10 mg/kg/day.

21. The method of claim 1 , wherein the dose of CBD is 20 mg/kg/day.

Assignees

• Gw Pharma Ltd
• Gw Res Ltd

Inventors

• Guy Geoffrey
• Wright Stephen
• Devinsky Orrin

Classifications

• A61K36/3482

  Cannabis · CPC title

• A61K36/185

  Magnoliopsida (dicotyledons) · CPC title

• A61K31/658 Primary

  o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol · CPC title

• A61K31/5517

  condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam · CPC title

• A61K31/53

  having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495}) · CPC title